Table 1.
Summary of patients characteristics
| Characteristics | Value | Percentage (%) |
|---|---|---|
| Age (years) | ||
| Median (range) | 56 (43–83) | |
| Gender | ||
| Male | 15 | 65.2 |
| Female | 8 | 34.8 |
| Country | ||
| US | 7 | 30.4 |
| Italy | 3 | 13.0 |
| Japan | 3 | 13.0 |
| Australia | 2 | 8.7 |
| France | 2 | 8.7 |
| UK | 2 | 8.7 |
| Irland | 1 | 4.3 |
| Korea | 1 | 4.3 |
| Portugal | 1 | 4.3 |
| Spain | 1 | 4.3 |
| Cancer type | ||
| Melanoma | 11 | 47.8 |
| Lung cancer | 7 | 30.4 |
| Bladder cancer | 1 | 4.3 |
| Breast cancer | 1 | 4.3 |
| Gastric cancer | 1 | 4.3 |
| Renal cell carcinoma | 1 | 4.3 |
| Parotid gland adenocarcinoma | 1 | 4.3 |
| Type of checkpoint inhibitor | ||
| PD-1 | 14 | 60.9 |
| PD-L1 | 4 | 17.4 |
| CTLA-4 | 1 | 4.3 |
| CTLA-4 + PD-1 | 2 | 8.7 |
| Othersa | 2 | 8.7 |
CTLA-4 cytotoxic T-lymphocyte antigen 4, PD-1 programmed cell death 1, PD-L1 programmed cell death ligand 1, UK United Kingdom, US United States
aOne was treated with ipilimumab followed by pembrolizumab, and the other received nivolumab followed by a combination of ipilimumab and nivolumab